VRDNViridian Therapeutics Inc
$17.90
$0.51
(2.93%)
Closed $17.90
$1.91
(10.67%)
After Hours
/filters:format(webp)https://news.stocktwits-cdn.com/large_Getty_Images_2269840000_jpg_55de2dda8b.webp)
EarningsAug 6
Mkt Cap$1.98B
Vol5.79M
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze...
Business Wire
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor...
Business Wire
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today...
Business Wire
Viridian Therapeutics (NASDAQ:VRDN) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Viridian Therapeutics in a research report on Tuesday...
MarketBeat
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today...
Business Wire
Promising Biotech Stocks To Watch Today - May 5th
Vertex Pharmaceuticals, Danaher, and Viridian Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop and commercialize biological products and technologiessuch as novel drugs, gene thera...
MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up on Strong Earnings
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up Following Earnings Beat...
MarketBeat
Markets On Fire: Biotech Breakthroughs and AI Mega-Deals Move Wall Street
$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks
24-7 Market News
<
1
2
...
>
Advertisement|Remove ads.
Latest VRDN News
ViewVRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
Stocktwits
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Business Wire
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Business Wire
Advertisement|Remove ads.